Key Points Clofarabine integrated in standard induction therapy for newly diagnosed AML reduces relapse probability but does not improve survival. Clofarabine improves survival in intermediate-risk AML categories ELN-1 and the AML genotype without NPM1 and without FLT3-ITD gene mutations.
No takes yet. Share an insight, caveat, or question.
Löwenberg et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: